(BIOT) Biotage - Ratings and Ratios
Exchange: ST • Country: Sweden • Currency: SEK • Type: Common Stock • ISIN: SE0000454746
BIOT: Laboratory, Equipment, Chemicals, Reagents, Systems, Solutions
Biotage AB (ST:BIOT) operates at the intersection of drug discovery, analytical testing, and environmental monitoring, offering a suite of solutions that streamline workflows across these sectors. Their product portfolio includes tools for organic and peptide synthesis, purification systems, and sample preparation solutions, all designed to enhance efficiency and precision in laboratories.
The company serves a diverse clientele, including pharmaceutical giants, biotech innovators, and contract research organizations, providing them with the necessary tools to accelerate drug development. Their global footprint spans over 80 countries, with a strong presence in the Americas, Europe, and Asia-Pacific, underscoring their ability to meet the needs of a worldwide customer base.
From a financial standpoint, Biotage boasts a market capitalization of 11,367 million SEK, with a price-to-earnings ratio of 43.16, indicating a valuation that reflects market confidence in their growth prospects. Their price-to-sales ratio of 5.37 highlights a premium pricing strategy, driven by the unique value their products deliver. The price-to-book ratio of 2.93 suggests that investors recognize the companys intangible assets and strategic positioning.
Investors may appreciate Biotages scalable business model, supported by high-margin products and a recurring revenue stream from consumables and services. Their focus on innovation and customer-centric solutions positions them well in a competitive landscape, making them an attractive consideration for those seeking exposure to the life sciences sector.
Additional Sources for BIOT Stock
BIOT Stock Overview
| Market Cap in USD | 819m |
| Sector | Healthcare |
| Industry | Medical Instruments & Supplies |
| GiC Sub-Industry | Life Sciences Tools & Services |
| IPO / Inception |
BIOT Stock Ratings
| Growth 5y | -8.24% |
| Fundamental | 45.2% |
| Dividend | 46.3% |
| Rel. Strength Industry | -46.3 |
| Analysts | - |
| Fair Price Momentum | 85.92 SEK |
| Fair Price DCF | 70.43 SEK |
BIOT Dividends
| Dividend Yield 12m | 1.19% |
| Yield on Cost 5y | 1.82% |
| Annual Growth 5y | 1.63% |
| Payout Consistency | 87.6% |
BIOT Growth Ratios
| Growth Correlation 3m | -86.6% |
| Growth Correlation 12m | -56.1% |
| Growth Correlation 5y | -3.6% |
| CAGR 5y | 2.45% |
| CAGR/Max DD 5y | 0.04 |
| Sharpe Ratio 12m | -0.63 |
| Alpha | -52.04 |
| Beta | 0.63 |
| Volatility | 61.24% |
| Current Volume | 206.2k |
| Average Volume 20d | 130.8k |
As of March 12, 2025, the stock is trading at SEK 99.35 with a total of 206,154 shares traded.
Over the past week, the price has changed by -5.65%, over one month by -28.42%, over three months by -39.79% and over the past year by -45.53%.
Partly, yes. Based on ValueRay Fundamental Analyses, Biotage (ST:BIOT) is currently (March 2025) ok to buy, but has to be watched. It has a ValueRay Fundamental Rating of 45.15 and therefor a somewhat positive outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of BIOT as of March 2025 is 85.92. This means that BIOT is currently overvalued and has a potential downside of -13.52%.
Biotage has no consensus analysts rating.
According to ValueRays Forecast Model, BIOT Biotage will be worth about 95.8 in March 2026. The stock is currently trading at 99.35. This means that the stock has a potential downside of -3.53%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | 155 | 56% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 95.8 | -3.5% |